Cerebral Small Vessel Diseases Clinical Trial
Official title:
Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial
A. the controlling of the blood pressure, especially the variation of blood pressure, can
slow down the development of the small vessel disease.
B intensive BP control is more effective than normal control of blood pressure in slowing
down the small vessel disease.
C drugs of Calcium Channel Blocker(CCB) and Angiotensin-Converting Enzyme Inhibitor(ACEI)
have no significant difference in lowing the blood pressure and variability of blood
pressure
The selected patients were diagnosis of stroke caused by small vessel disease due to
hypertension recently.
The patients had been divided into two groups by random principle and given ACEI or CCB
separately for treatment. At the same time, given intensive or regular controlling of the
blood pressure by stratified random. In the regular controlling group, the BP should be in
the range of 130-139 mmHg and in the intensive controlling group, the BP should be below 130
mmHg. To the acute ischemic stroke patients who were accord with the lacunar infarction
syndrome, it is rule to do the examination for exclusive selection of exclusion of
hemodynamic dysfunction due to the artery stenosis ( stenosis >50%, the examination of
intracranial artery was by the methods of Transcranial Doppler (TCD)/Magnetic Resonance
Angiography(MRA)/Computed Tomographic Angiography(CTA)/Digital Subtraction Angiography(DSA),
the examination of carotid artery was by the methods of colorful ultrasound / MRA/ CTA/ DSA
) at the baseline.
It should be proved of lacunar infarction by brain imaging. All patients had a MRI scan at
the baseline and the beginning of the research, including T1-Weighted
Imaging(T1W1),T2-Weighted Imaging(T2WI), T2-FLAIR, Diffusion-Weighted Imaging(DWI),
Gradient-Recalled Echo(GRE) T2*, the Perfusion-Weighted Imaging(PWI) would complete
conditionally (100 cases). The details should be followed by the instruction in the
appendix.
Research about the variability of blood pressure: all patients show complete the examination
of 24-hour blood-pressure monitor (at the baseline, the first month after the beginning,
every three months and the end of the research), complete the head-up tilt test if
conditionally ( at the baseline, each 3 months later and the end of the research ) The
automatic regulation function of the small vessel should be evaluated if conditionally (the
C02 reaction, TCD head-up tilt) and also the function of endothelium-derived relaxing of the
brachial artery (at the baseline, each 3 months later and the end of the research) The
reservation of the blood was for further research on genetic study.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04041349 -
Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease
|
Phase 4 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Not yet recruiting |
NCT05967728 -
Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
|
Phase 2 | |
Completed |
NCT05714813 -
Circuit Training and Retina
|
N/A | |
Not yet recruiting |
NCT06077305 -
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
|
||
Not yet recruiting |
NCT06061692 -
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)
|
Phase 4 | |
Recruiting |
NCT04962295 -
China Imaging-based Biobank of Cerebral Small Vessal Diseases
|
||
Completed |
NCT02801032 -
Effect of Tadalafil on Cerebral Large Arteries in Stroke
|
Phase 2 | |
Not yet recruiting |
NCT05594966 -
Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
|
||
Terminated |
NCT02890888 -
Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease
|
N/A | |
Recruiting |
NCT04318119 -
Cerebral Small Vessel Disease Registry Study
|
||
Recruiting |
NCT03906123 -
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
|
N/A | |
Recruiting |
NCT05306834 -
Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease
|
N/A | |
Not yet recruiting |
NCT05583266 -
Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
|
Phase 4 | |
Recruiting |
NCT05173896 -
Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial
|
Phase 2 | |
Recruiting |
NCT01688505 -
Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function
|
N/A | |
Recruiting |
NCT04330222 -
Cambridge 7 Tesla Cerebral Small Vessel Disease Study
|
||
Recruiting |
NCT04298866 -
White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI
|
N/A | |
Not yet recruiting |
NCT06319495 -
Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
|
N/A |